La piel: un testigo silencioso en la esclerosis sistémica

  • Claudia Marcela Arenas
  • Paola Andrea Olaya
Palabras clave: esclerosis, tejido conjuntivo, esclerodermia, esclerodermia limitada, esclerodermia difusa

Resumen

Son varios los hallazgos cutáneos que sugieren al dermatólogo el diagnóstico de esclerosis sistémica; entre ellos, se describen: disminución de la apertura oral, pérdida de arrugas faciales, fenómeno de Raynaud, megacutícula, esclerodactilia, calcificaciones y cambios en la pigmentación de la piel, esclerosis cutánea y alteraciones en la capilaroscopia. Muchos de estos hallazgos dermatológicos nos permiten orientar el diagnóstico, clasificar la enfermedad, indicar un tratamiento oportuno y evaluar el pronóstico, por lo cual es importante conocerlos. Se revisan los hallazgos dermatológicos en pacientes con esclerosis sistémica.

Biografía del autor/a

Claudia Marcela Arenas

Médica dermatóloga, especialista en Docencia Universitaria, Centro Dermatológico Federico Lleras Acosta, Bogotá, D.C., Colombia

Paola Andrea Olaya

Médica, residente de tercer año de Dermatología, Fundación Universitaria Sanitas-Centro Dermatológico Federico Lleras Acosta, Bogotá, D.C., Colombia.

Citas

1. Balbir-Gurman A, Baun-Moscovici Y. Scleroderma – New aspects in pathogenesis and treatment. Best Pract Res Clin Rheumatol. 2012;26:13-24.
2. Unanue L, González MR, Gardeazábal J. Esclerodermia (sclerosis sistémica). Piel. 2010;25:252-66.
3. Katsumoto TR, Whitfield ML, Connolly MK. The pathogenesis of systemic sclerosis. Annu Rev Pathol. 2011;6:509-37.
4. Szekanecz Z, Koch AE. Endothelial cells in inflammation and angiogenesis. Curr Drug Targets. 2005;4:319-23.
5. Sticherling M. Systemic sclerosis - dermatological aspects. Part 1: Pathogenesis, epidemiology, clinical findings. J Dtsch Dermatol Ges. 2012;10:705-16.
6. Mayes MD. Scleroderma epidemiology. Rheum Dis Clin North Am. 2003;29:239-54.
7. Chifflot H, Fautzi B, Sordet C, Chatelus E, Sibilia J. Incidence and prevalence of systemic sclerosis: A systematic literature review. Semin Arthritis Reum. 2008;37:223-35.
8. Laing TJ, Gillespie BW, Toth MB, Mayes MD, Gallavan Jr RH, Burns CJ, et al. Racial differences in scleroderma among women in Michigan. Arthritis Rheum. 1997;40:734-42.
9. Vancheeswaran R, Black CM, David J, Hasson N, Harper J, Atherton D, et al. Childhood-onset scleroderma: Is it different from adult-onset disease. Arthritis Rheum. 1996;39:1041-9.
10. Scalapino K, Arkachaisri T, Lucas M, Fertig N, Helfrich DJ, Londino Jr AV, et al. Childhood onset systemic sclerosis: Classification, clinical and serologic features, and survival in comparison with adult onset disease. J Rheumatol. 2006;33:1004-13.
11. Janet E. Pope, Sindhu R. Johnson. New Classification Criteria for Systemic Sclerosis (Scleroderma). Rheum Dis Clin N Am 41. 2015; 383–98.
12. LeRoy EC, Medsger Jr TA. Criteria for the classification of early systemic sclerosis. J Rheumatol. 2001;28:1573.
13. Poormoghim H, Lucas M, Fertig N, Medsger Jr TA. Systemic sclerosis sine scleroderma: Demographic, clinical and serologic features and survival in forty-eight patients. Arthritis Rheum. 2000;43:444-51.
14. Arnson Y, Amital H, Guiducci S, Matucci-Cerinic M, Valentini G, Barzilai O, et al. The role of infections in the immunopathogenesis of systemic sclerosis evidence from serological studies. Ann N Y Acad Sci. 2009;1173:627-32.
15. Mora GF. Systemic sclerosis: Environmental factors. J Rheumatol. 2009;36:2383-96.
16. Viswanath V, Phiske M, Gopalani V. Systemic sclerosis: Current concepts in pathogenesis and therapeutic aspects of dermatology manifestations. Indian J Dermatol. 2013;58:255-69.
17. Mahoney WM Jr, Fleming JN, Schwartz SM. A unifying hypothesis for scleroderma: identifying a target cell for scleroderma. Curr Rheumatol Rep. 2011;13:28-36.
18. Wigley FM. Clinical practice. Raynaud’s phenomenon. N Engl J Med. 2002;347:1001-8.
19. Tolosa C, Simeon C, Gabarro L. El fenómeno de Raynaud. Med Clin. 2009;132:712-8.
20. Nietsche A. Raynaud, úlceras digitales y calcinosis en esclerodermia. Reumatol Clinic. 2012;8:270-7.
21. Strange G, Nash P. The manifestation of vasculophaty in systemic sclerosis and its evidence based therapy. Int J Rheum Dis. 2009;12:192-206.
22. Jones S. Skin manifestations of systemic disease. Medicine. 2004;32:40-3.
23. Chung L, Lin J, Furst D, Fiorentino D. Systemic and localizated scleroderma. Clin Dermatol. 2006;24:374-92.
24. Krieg T, Takehara K. Skin disease: A cardinal feature of systemic sclerosis. Rheumatology. 2009;48:14-8.
25. Steen V, Denton CP, Pope JE, Matucci-Cerinic M. Digital ulcers: Overt vascular disease in systemic sclerosis. Rheumatology (Oxford). 2009;4(Suppl.3):19-24.
26. Arenas C, Jiménez J, González MI. Úlcera digital como manifestación inicial de esclerodermia sistémica cutánea límitada. Rev Asoc Colomb Dermatol.2013;21:360-3.
27. Amanzi L, Braschi F, Fiori G, Galluccio F, Miniati I, Giudicci S, et al. Digital ulcers in scleroderma: Staging, characteristics and sub-setting through observation of 1614 lesions. Rheumatology. 2010;49:1374-82.
28. Alivernini S, De Santis M, Tolusso B, Mannocci A, Bosello SL, Peluso G, et al. Skin ulcers in systemic sclerosis: Determinants of presence and predictive factors of healing. J Am Acad Dermatol. 2009;60:426-35.
29. Tabata H, Hara N, Otsuka S, Yamakage A, Yamazaki S, Koibuchi N. Correlation between diffuse pigmentation and keratinocyte derived endothelin-1 in systemic sclerosis. Int J Dermatol. 2000;39:899-902.
30. Boulman N, Slobodin G, Rozenbaum M, Rosner I. Calcinosis in rheumatic diseases. Semin Artritis Rheum. 2005;34:805-12.
31. Davies CA, Jeziorska M, Freemont AJ, Herrick AL. Expression of osteonectin and matrix Gla protein in scleroderma patients with and without calcinosis. Rheumatology.2006;45:1349-55.
32. Czirjak L, Foeldvari I, Muller-Ladner U. Skin Involvement in systemic sclerosis. Rheumatology. 2008;47:44-5.
33. Pope JE. Musculoskeletal involvement in scleroderma. Rheum Dis Clin North Am.2003;29:391-408.
34. Clements PJ, Furst DE, Campion DS, Bohan A, Harris R, Levy J, Paulus HE. Muscle disease in progressive systemic sclerosis: Diagnostic and therapeutic considerations. Arthritis Rheum.1978;21:62-71.
35. Denton C, Black C. Scleroderma (Systemic sclerosis). In: Wolff K, Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, editors. Fitzpatrick´s Dermatology in General Medicine. Seventh edition. New York: McGraw-Hill; 2008. p. 1553-62.
36. Chojnowski MM, Felis-Giemza A, Olesinska M. Capillaroscopy-a role in modern rheumatology. Rheum.2016;54:67-72.
37. Cutulo M, Sulli A, Pizzorni C, Accardo S. Nailfold videocapillaroscopy assesment of microvascular damage in systemic sclerosis. J Rheumatol. 2000;27:155-160.
38. Sebastiani M, Manfredi A, Colaci M, D’amico R, Malagoli V, Giuggioli D, Ferri C. Capillaroscopic skin ulcer risk index: A new prognostic tool for digital skin ulcer development in systemic sclerosis patients. Arthritis Rheum.2009;61:688-94.
39. Sebastiani M, Manfredi A, Vukatana G, Moscatelli S, Riato L, Bocci M,et al. Predictive role of capillaroscopic skin ulcer risk index in systemic sclerosis: A multicenter validation study. Ann Rheum Dis.2012;71:67-70.
40. Sticherling M. Systemic sclerosis - focus on dermatological aspects. Part 2: Diagnostics, therapy. J Dtsch Dermatol Ges. 2012;10:783-91.
41. Klein-Weigel P, Opitz C, Riemekasten G. Systemic sclerosis: A systematic overview. Part 1. Disease characteristics and classification, pathophysiologic concepts, and recommendations for diagnosis and surveillance. Vasa. 2011;40:6-19.
42. Grassegger A, Pohla-Gubo G, Frauscher M, Hintner H. Autoantibodies in systemic sclerosis (scleroderma): Clues for clinical evaluation, prognosis and pathogenesis. Wien Med Wochenschr. 2008;158:19-28.
43. Ho KT, Reveille JD. The clinical relevance of autoantibodies in scleroderma. Arthritis Res Ther. 2003;5:80-93
44. Czömpóly T, Simon D, Czirják L, Németh P. Anti-topoisomerasa I autoantibodies in systemic sclerosis. Autoimmun Rev. 2009;8:692-6.
45. Black CM. Measurement of skin involvement in scleroderma. J Rheumatol. 1995;22:1217-9.
46. Amjadi S, Maranian P, Furst DE, Clements PJ, Wong WK, Postlethwaite AE, et al. Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: Analysis of three large multicenter, double-blind, randomized con- trolled trials. Arthritis Rheum. 2009;60:2490-8.
47. Walker UA, Tyndall A, Czirjak L, Denton C, Farge-Bancel D, Kowal-Bielecka O, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: A report from the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis. 2007;66:754-63.
48. Vitiello M, Abuchar A, Santana N, Dehesa L, Kerdel FA. An update on the treatment of the cutaneous manifestation of systemic sclerosis: The dermatologist’s point of view. J Clin Aesthet Dermatol. 2012;5:33-43.
49. Kowal-Bieleka O, Landewe R, Avouac J, Chwiesko S, Miniati I, Czirjak L, et al. EULAR recommendations for the treatment of systemic sclerosis: A report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis. 2009;68:620-8.
50. Meyer O. Prognostic markers for systemic sclerosis. Joint Bone Spine. 2006;73:490-4.
51. Steen VD. The lung in systemic sclerosis. J Clin Rheumatol. 2005;11:40-6.
52. Ioannidis JP, Vlachoyiannopoulos PG, Haidich AB, Medsger Jr TA, Lucas M, Michet CJ, et al. Mortality in systemic sclerosis: An international meta-analysis of individual patient data. Am J Med. 2005;118:2-10.
Cómo citar
1.
Arenas CM, Olaya PA. La piel: un testigo silencioso en la esclerosis sistémica. rev. asoc. colomb. dermatol. cir. dematol. [Internet]. 1 de octubre de 2016 [citado 5 de julio de 2022];24(4):279-8. Disponible en: https://revista.asocolderma.org.co/index.php/asocolderma/article/view/291

Descargas

La descarga de datos todavía no está disponible.
Publicado
2016-10-01
Sección
Artículo de revisión

Artículos más leídos del mismo autor/a